Skip to main content
. 2021 Oct 1;19:223. doi: 10.1186/s12916-021-02089-z

Fig. 3.

Fig. 3

Distribution of treatments and its association with clinical outcomes measured by PFS and OS. A Distribution of treatments in patients carrying alterations with different actionability levels. B PFS and OS in patients carrying potentially actionable alterations who were treated with a matched therapy and a nonmatched therapy